Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • Blog
    • Cardiology Update:...

    Cardiology Update: Partner 2A trial

    Dr. Prem AggarwalWritten by Dr. Prem Aggarwal Published On 2016-05-02T16:37:26+05:30  |  Updated On 2 May 2016 4:37 PM IST
    Cardiology Update: Partner 2A trial
    PARTNER 2A Trial-Is TAVR better than SAVR in intermediate risk patients?

    Transcatheter Aortic Valve Replacement (TAVR) has been found to be superior to the standard surgical treatment in patients with severe aortic stenosis. In Partner trial inoperable patients and the patients with unacceptable surgical risks were tried and were found that in these two cohorts of patients TAVR was found to be better than SAVR. In further trial partner 2 A were tried in better conditions with better operator experiences and even the second generation SAPIEN XT TAVR and in this trial patient with intermediate risk for surgical were taken.

    In the PARTNER 2A randomized trial, the PARTNER investigators compared the safety and effectiveness of the second generation SAPIEN XT TAVR system with conventional surgery in intermediate-risk patients.

    A total of 2032 intermediate-risk patients (mean age, 81.6 years; 54% male) with symptomatic severe AS were randomly assigned at 57 clinical centers (55 in the U.S. and 2 in Canada) to undergo either TAVR or surgical aortic valve replacement (SAVR). Surgical risk was determine by a multi-disciplinary Heart Team using a guideline of STS score ≥4%, and was adjudicated by case review committee (mean STS score was 5.8%). Of those who underwent TAVR, 775 had transfemoral access and 236 had transapical or transaortic access (combined as transthoracic access).

    For the primary endpoint of death from any cause or disabling stroke (modified Rankin score of 2 or greater at 90 days) at 2 years, no difference was noted between groups (p=0.001 for noninferiority). The 2-year Kaplan-Meier event rates were 19.3% for TAVR and 21.1% for SAVR (hazard ratio [HR], 0.89; p (log rank) =0.25).

    With transfemoral access, TAVR results in a lower death/disabling stroke rate than SAVR (HR, 0.79; p=0.05), whereas in the transthoracic-access cohort, the outcomes were similar.

    Mean anesthesia time was significantly lower with TAVR, as was procedure time and median ICU stay and total hospital stay. Compared to SAVR, TAVR was associated with a larger aortic-valve area, lower rates of acute kidney injury, life-threatening or disabling bleeding, and new-onset atrial fibrillation. SAVR, however, was associated with fewer major vascular complications and less paravalvular aortic regurgitation.

    The researches concluded that even in intermediate risk patients with symptomatic severe AS the TAVR with SAPIEN XT system is safe and is better for the primary endpoint of death and disabling stroke at 2 years. In those who had transfemoral access TAVR (76% of patients), TAVR significantly reduced all-cause death and disabling stroke compared to SAVR.


    “The researches also commented that the results from PARTNER 2A support the use of TAVR as an alternative to surgery in intermediate risk patients, similar to those in this trial,” . “In patients who care candidates for transfemoral access, TAVR may result in additional clinical advantages.” Long-term durability assessments of these bioprosthetic valves are still lacking, and “extrapolation of these findings to low-risk patients requires further clinical trial validation,”

    References

    • CR Smith, Presenter: ACC 2016 Late-Breaking Clinical Trial: PARTNER 2A Final Results: Transcatheter aortic valve replacement compared with surgery in intermediate risk patients with aortic stenosis ACC 2016. Apr 2, 2016.

    • MD Leon, CR Smith, MJ Mack, et al. (JG Webb, senior author): Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2 Apr, 2016 Published online ahead of print.

    • NE Moat: Will TAVR become the predominant method for treating severe aortic stenosis? N Engl J Med. 2 Apr, 2016 Published online ahead of print.

    bioprosthetic valvesPartner 2A trialSAPIEN XT systemSAVRTAVR is better than SAVRtranscatheter aortic valve replacement (TAVR)
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Dr. Prem Aggarwal
    Dr. Prem Aggarwal

      Dr Prem Aggarwal, (MD, DNB Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder of Medical Dialogues. He is the Chairman of Sanjeevan Hospital in Central Delhi and also serving as the member of Delhi Medical Council

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok